Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models

Ernst Lengyel, Lacey M. Litchfield, Anirban Mitra, Kristin M. Nieman, Abir Mukherjee, Yilin Zhang, Alyssa Johnson, Michael Bradaric, Wooseok Lee, Iris L. Romero

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Objective There is increasing preclinical evidence indicating that metformin, a medication commonly used for type 2 diabetes mellitus, may protect against cancer. Motivated by this emerging evidence we asked 2 questions: (1) can metformin prevent ovarian cancer growth by altering metabolism and (2) will metformin increase sensitivity to chemotherapy. Study Design The effect of metformin in ovarian cancer was tested in vitro and with 2 different mouse models. In vitro, cell lines (n = 6) were treated with metformin (10-40 mmol/L) or phosphate-buffered saline solution and cellular proliferation and metabolic alterations (adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis) were compared between the 2 groups. In mouse models, a prevention study was performed by treating mice with metformin (250 mg/kg/d intraperitoneally) or placebo for 2 weeks followed by intraperitoneal injection of the SKOV3ip1 human ovarian cancer cell line, and the mean number of tumor implants in each treatment group was compared. In a treatment study, the LSL-K-rasG12D/+/PTENfloxP/floxP genetic mouse model of ovarian cancer was used. Mice were treated with placebo, paclitaxel (3 mg/kg/wk intraperitoneally for 7 weeks), metformin (100 mg/kg/d in water for 7 weeks), or paclitaxel plus metformin, and tumor volume was compared among treatment groups. Results In vitro, metformin decreased proliferation of ovarian cancer cell lines and induced cell cycle arrest, but not apoptosis. Further analysis showed that metformin altered several aspects of metabolism including adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis. In the prevention mouse model, mice that were pretreated with metformin had 60% fewer tumor implants compared with controls (P <.005). In the treatment study, mice that were treated with paclitaxel plus metformin had a 60% reduction in tumor weight compared with controls (P =.02), which is a level of tumor reduction greater than that resulting from either paclitaxel or metformin alone. Conclusion Based on these results, we conclude that metformin alters metabolism in ovarian cancer cells, prevents tumor growth, and increases sensitivity to chemotherapy in vitro and in mouse models. These preclinical findings suggest that metformin warrants further investigation for use as an ovarian cancer therapeutic.

Original languageEnglish (US)
Pages (from-to)479.e1-479.e10
JournalAmerican Journal of Obstetrics and Gynecology
Volume212
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Metformin
Paclitaxel
Ovarian Neoplasms
Growth
Glycolysis
Adenosine Monophosphate
Neoplasms
Tumor Burden
Cell Line
Protein Kinases
Placebos
Lipids
Therapeutics
Drug Therapy
Genetic Models
Cell Cycle Checkpoints
Intraperitoneal Injections
Sodium Chloride
Type 2 Diabetes Mellitus

Keywords

  • cancer
  • metabolism
  • metformin
  • mouse model
  • ovarian cancer
  • prevention

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. / Lengyel, Ernst; Litchfield, Lacey M.; Mitra, Anirban; Nieman, Kristin M.; Mukherjee, Abir; Zhang, Yilin; Johnson, Alyssa; Bradaric, Michael; Lee, Wooseok; Romero, Iris L.

In: American Journal of Obstetrics and Gynecology, Vol. 212, No. 4, 01.04.2015, p. 479.e1-479.e10.

Research output: Contribution to journalArticle

Lengyel, E, Litchfield, LM, Mitra, A, Nieman, KM, Mukherjee, A, Zhang, Y, Johnson, A, Bradaric, M, Lee, W & Romero, IL 2015, 'Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models', American Journal of Obstetrics and Gynecology, vol. 212, no. 4, pp. 479.e1-479.e10. https://doi.org/10.1016/j.ajog.2014.10.026
Lengyel, Ernst ; Litchfield, Lacey M. ; Mitra, Anirban ; Nieman, Kristin M. ; Mukherjee, Abir ; Zhang, Yilin ; Johnson, Alyssa ; Bradaric, Michael ; Lee, Wooseok ; Romero, Iris L. / Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. In: American Journal of Obstetrics and Gynecology. 2015 ; Vol. 212, No. 4. pp. 479.e1-479.e10.
@article{dac0a53590f645a1ae7d17a862f56e89,
title = "Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models",
abstract = "Objective There is increasing preclinical evidence indicating that metformin, a medication commonly used for type 2 diabetes mellitus, may protect against cancer. Motivated by this emerging evidence we asked 2 questions: (1) can metformin prevent ovarian cancer growth by altering metabolism and (2) will metformin increase sensitivity to chemotherapy. Study Design The effect of metformin in ovarian cancer was tested in vitro and with 2 different mouse models. In vitro, cell lines (n = 6) were treated with metformin (10-40 mmol/L) or phosphate-buffered saline solution and cellular proliferation and metabolic alterations (adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis) were compared between the 2 groups. In mouse models, a prevention study was performed by treating mice with metformin (250 mg/kg/d intraperitoneally) or placebo for 2 weeks followed by intraperitoneal injection of the SKOV3ip1 human ovarian cancer cell line, and the mean number of tumor implants in each treatment group was compared. In a treatment study, the LSL-K-rasG12D/+/PTENfloxP/floxP genetic mouse model of ovarian cancer was used. Mice were treated with placebo, paclitaxel (3 mg/kg/wk intraperitoneally for 7 weeks), metformin (100 mg/kg/d in water for 7 weeks), or paclitaxel plus metformin, and tumor volume was compared among treatment groups. Results In vitro, metformin decreased proliferation of ovarian cancer cell lines and induced cell cycle arrest, but not apoptosis. Further analysis showed that metformin altered several aspects of metabolism including adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis. In the prevention mouse model, mice that were pretreated with metformin had 60{\%} fewer tumor implants compared with controls (P <.005). In the treatment study, mice that were treated with paclitaxel plus metformin had a 60{\%} reduction in tumor weight compared with controls (P =.02), which is a level of tumor reduction greater than that resulting from either paclitaxel or metformin alone. Conclusion Based on these results, we conclude that metformin alters metabolism in ovarian cancer cells, prevents tumor growth, and increases sensitivity to chemotherapy in vitro and in mouse models. These preclinical findings suggest that metformin warrants further investigation for use as an ovarian cancer therapeutic.",
keywords = "cancer, metabolism, metformin, mouse model, ovarian cancer, prevention",
author = "Ernst Lengyel and Litchfield, {Lacey M.} and Anirban Mitra and Nieman, {Kristin M.} and Abir Mukherjee and Yilin Zhang and Alyssa Johnson and Michael Bradaric and Wooseok Lee and Romero, {Iris L.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.ajog.2014.10.026",
language = "English (US)",
volume = "212",
pages = "479.e1--479.e10",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models

AU - Lengyel, Ernst

AU - Litchfield, Lacey M.

AU - Mitra, Anirban

AU - Nieman, Kristin M.

AU - Mukherjee, Abir

AU - Zhang, Yilin

AU - Johnson, Alyssa

AU - Bradaric, Michael

AU - Lee, Wooseok

AU - Romero, Iris L.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective There is increasing preclinical evidence indicating that metformin, a medication commonly used for type 2 diabetes mellitus, may protect against cancer. Motivated by this emerging evidence we asked 2 questions: (1) can metformin prevent ovarian cancer growth by altering metabolism and (2) will metformin increase sensitivity to chemotherapy. Study Design The effect of metformin in ovarian cancer was tested in vitro and with 2 different mouse models. In vitro, cell lines (n = 6) were treated with metformin (10-40 mmol/L) or phosphate-buffered saline solution and cellular proliferation and metabolic alterations (adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis) were compared between the 2 groups. In mouse models, a prevention study was performed by treating mice with metformin (250 mg/kg/d intraperitoneally) or placebo for 2 weeks followed by intraperitoneal injection of the SKOV3ip1 human ovarian cancer cell line, and the mean number of tumor implants in each treatment group was compared. In a treatment study, the LSL-K-rasG12D/+/PTENfloxP/floxP genetic mouse model of ovarian cancer was used. Mice were treated with placebo, paclitaxel (3 mg/kg/wk intraperitoneally for 7 weeks), metformin (100 mg/kg/d in water for 7 weeks), or paclitaxel plus metformin, and tumor volume was compared among treatment groups. Results In vitro, metformin decreased proliferation of ovarian cancer cell lines and induced cell cycle arrest, but not apoptosis. Further analysis showed that metformin altered several aspects of metabolism including adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis. In the prevention mouse model, mice that were pretreated with metformin had 60% fewer tumor implants compared with controls (P <.005). In the treatment study, mice that were treated with paclitaxel plus metformin had a 60% reduction in tumor weight compared with controls (P =.02), which is a level of tumor reduction greater than that resulting from either paclitaxel or metformin alone. Conclusion Based on these results, we conclude that metformin alters metabolism in ovarian cancer cells, prevents tumor growth, and increases sensitivity to chemotherapy in vitro and in mouse models. These preclinical findings suggest that metformin warrants further investigation for use as an ovarian cancer therapeutic.

AB - Objective There is increasing preclinical evidence indicating that metformin, a medication commonly used for type 2 diabetes mellitus, may protect against cancer. Motivated by this emerging evidence we asked 2 questions: (1) can metformin prevent ovarian cancer growth by altering metabolism and (2) will metformin increase sensitivity to chemotherapy. Study Design The effect of metformin in ovarian cancer was tested in vitro and with 2 different mouse models. In vitro, cell lines (n = 6) were treated with metformin (10-40 mmol/L) or phosphate-buffered saline solution and cellular proliferation and metabolic alterations (adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis) were compared between the 2 groups. In mouse models, a prevention study was performed by treating mice with metformin (250 mg/kg/d intraperitoneally) or placebo for 2 weeks followed by intraperitoneal injection of the SKOV3ip1 human ovarian cancer cell line, and the mean number of tumor implants in each treatment group was compared. In a treatment study, the LSL-K-rasG12D/+/PTENfloxP/floxP genetic mouse model of ovarian cancer was used. Mice were treated with placebo, paclitaxel (3 mg/kg/wk intraperitoneally for 7 weeks), metformin (100 mg/kg/d in water for 7 weeks), or paclitaxel plus metformin, and tumor volume was compared among treatment groups. Results In vitro, metformin decreased proliferation of ovarian cancer cell lines and induced cell cycle arrest, but not apoptosis. Further analysis showed that metformin altered several aspects of metabolism including adenosine monophosphate-activated protein kinase activity, glycolysis, and lipid synthesis. In the prevention mouse model, mice that were pretreated with metformin had 60% fewer tumor implants compared with controls (P <.005). In the treatment study, mice that were treated with paclitaxel plus metformin had a 60% reduction in tumor weight compared with controls (P =.02), which is a level of tumor reduction greater than that resulting from either paclitaxel or metformin alone. Conclusion Based on these results, we conclude that metformin alters metabolism in ovarian cancer cells, prevents tumor growth, and increases sensitivity to chemotherapy in vitro and in mouse models. These preclinical findings suggest that metformin warrants further investigation for use as an ovarian cancer therapeutic.

KW - cancer

KW - metabolism

KW - metformin

KW - mouse model

KW - ovarian cancer

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=84930389542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930389542&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2014.10.026

DO - 10.1016/j.ajog.2014.10.026

M3 - Article

C2 - 25446664

AN - SCOPUS:84930389542

VL - 212

SP - 479.e1-479.e10

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -